For the quarter ending 2025-09-30, ECL had $34,900K increase in cash & cash equivalents over the period. $529,700K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income including noncontrolling interest | 589,700 | 528,500 | 406,500 | 479,500 |
| Depreciation | 165,900 | 166,700 | 161,200 | 161,200 |
| Amortization | 76,600 | 75,000 | 74,900 | 74,300 |
| Deferred income taxes | 3,600 | -39,700 | -21,000 | -40,800 |
| Share-based compensation expense | 33,600 | 33,700 | 42,200 | 25,300 |
| Pension and postretirement plan contributions | 38,100 | 13,400 | 15,600 | 10,700 |
| Pension and postretirement plan expense (income), net | 3,500 | 3,500 | 3,400 | 2,800 |
| Restructuring charges, net of cash paid | -17,900 | -16,400 | 21,800 | 35,400 |
| Sale of global surgical solutions business | 0 | 0 | -1,100 | -1,000 |
| Other, net | -13,600 | -11,200 | 4,400 | -6,600 |
| Accounts receivable | 27,900 | 113,300 | 9,100 | 37,400 |
| Inventories | -39,300 | 7,800 | 69,100 | -48,000 |
| Other assets | -11,800 | -52,200 | 29,900 | -16,800 |
| Accounts payable | -55,200 | 9,900 | -2,500 | 22,300 |
| Other liabilities | -7,200 | 11,700 | -190,100 | -17,600 |
| Cash provided by operating activities | 791,300 | 701,800 | 369,400 | 766,700 |
| Capital expenditures | 261,600 | 216,700 | 237,900 | 359,700 |
| Property and other assets sold | 4,000 | 20,800 | 21,600 | 8,000 |
| Acquisitions and investments in affiliates, net of cash acquired | 0 | 500 | - | 256,500 |
| Divestiture of businesses, net of cash divested | 0 | 0 | -14,900 | 0 |
| Other, net | 23,000 | 28,000 | -7,200 | 19,300 |
| Cash (used for) provided by investing activities | -280,600 | -224,400 | -224,000 | -627,500 |
| Net issuances of commercial paper and notes payable | 1,900 | -5,300 | 4,500 | -1,400 |
| Long-term debt borrowings | 519,000 | 500,000 | - | - |
| Long-term debt repayments | 674,200 | - | - | 0 |
| Reacquired shares | 175,400 | 45,500 | 153,700 | 2,800 |
| Dividends paid | 184,400 | 188,000 | 192,000 | 161,400 |
| Exercise of employee stock options | 43,000 | 40,500 | 98,500 | 26,600 |
| Hedge settlements | - | - | - | 0 |
| Other, net | -7,300 | -4,400 | 1,100 | -1,100 |
| Cash used for financing activities | -477,400 | 297,300 | -241,600 | -140,100 |
| Effect of exchange rate changes on cash and cash equivalents | 1,600 | -16,400 | 2,000 | -3,400 |
| Increase in cash and cash equivalents | 34,900 | 758,300 | -94,200 | -4,300 |
| Cash and cash equivalents at beginning of period | 1,920,900 | 1,162,600 | 1,256,800 | 1,261,100 |
| Cash and cash equivalents at end of period | 1,955,800 | 1,920,900 | 1,162,600 | 1,256,800 |
ECOLAB INC. (ECL)
ECOLAB INC. (ECL)